All data is based on simulations and can be recalculted using the supplied web application.

1. Introduction {#sec001}
===============

Epidemiology relies on accurately capturing the disease status of subjects within a certain population. Inaccuracies in obtaining the disease status might (strongly) bias the epidemiological findings. Particularly electronic healthcare record (eHR) databases, which have become a prominent source of information in pharmacoepidemiology, are prone the disease misclassification. eHR databases capture healthcare provided to large populations, their size permits the study of rare events and their establishment within clinical practices enables studying real-world effects of pharmaceutical products in a timely and cost-efficient manner. However, although eHR databases provide a valuable source of data for pharmacoeopidemiological research, these data are collected primarily for clinical and administrative use rather than for research and as such, concerns regarding data quality exist \[[@pone.0231333.ref001], [@pone.0231333.ref002]\].

Research using eHR databases relies on case-finding algorithms (CFAs), by which subjects captured by the database are classified as diseased or non-diseased, without additional contact with them. The accuracy of the CFA to classify patients depends on the database quality and completeness, the disease of interest and the patient group being studied \[[@pone.0231333.ref003]\]. Validation of the CFAs, by which the CFA classifications are compared to a reference standard (e.g. chart review, register), is increasingly considered an essential component of eHR database research \[[@pone.0231333.ref003]--[@pone.0231333.ref005]\]. The validity of the CFAs can be measured by different validity indices; the most commonly used ones are sensitivity (*SE*), specificity (*SP*) positive and negative predictive value (*PPV* and *NPV*). Once the values of such validity indices are known, the observed prevalence or risk estimates can be corrected for misclassification \[[@pone.0231333.ref006], [@pone.0231333.ref007]\].

Despite being considered essential, validation studies are rarely performed because they are very time- and resource intensive \[[@pone.0231333.ref003]\]. On top, most validation studies only report on *SE* and *PPV* as validation cohorts often do not include subjects without the disease (bench). In this paper, we show how validity indices can be analytically derived from each other.

2. Methods {#sec002}
==========

2.1. Definitions {#sec003}
----------------

A CFA is typically validated by comparing its classifications with that of a reference standard. When the reference standard is assumed to perfectly represent the true dichotomous disease status (i.e. the reference standard is error-free), it is also called the 'gold standard'. The validation data is conventionally captured in a 2 x 2-table representing the joint probability distribution of the CFA-derived classification and the 'gold standard' ([Table 1](#pone.0231333.t001){ref-type="table"}). In this representation, *SE* is the proportion of patients with the disease of interest who are CFA-positive, *SP* is the proportion of persons without the disease who are CFA-negative, *PPV* is the proportion of CFA-positive patients who have the disease of interest and *NPV* is the proportion of CFA-negative persons without the disease of interest. These four validity indices are all conditional probabilities, where *SE*, *SP*, *PPV* and *NPV* are conditioned on the number of diseased, non-diseased, CFA-positives and CFA-negatives, respectively ([Table 1](#pone.0231333.t001){ref-type="table"}). The observed prevalence (*P*) is then the proportion of CFA-positives and the true prevalence (*π*) the proportion of diseased among all N subjects. Obtaining the true prevalence is not always possible and requires an error-free test. Note that the observed prevalence and the four validity indices are all CFA-dependent.

10.1371/journal.pone.0231333.t001

###### Validity indices for dichotomous data: Sensitivity (SE), specificity (SP) positive (PPV) and negative predictive value (NPV) the observed (P) and true prevalence (π).

![](pone.0231333.t001){#pone.0231333.t001g}

  ------------------------ --------------------------- -------------------------- --------------------------- --------------------
                                                       'Gold' standard                                        

                                                       Positive                   Negative                    Validity index

  Case Finding Algorithm   Positive                    Nr. of True positives TP   Nr. of False positives FP   *PPV* = TP/(TP+FP)

  Negative                 Nr. of False negatives FN   Nr. of True negatives TN   *NPV* = TN/(FN+TN)          

                           Validity index              *SE* = TP/(TP + FN)        *SP* = TN/(FP + TN)         N = TP+FP+FN+TN\
                                                                                                              *P* = (TP+FP)/N\
                                                                                                              *π* = (TP+FN)/N
  ------------------------ --------------------------- -------------------------- --------------------------- --------------------

2.2. Interrelationships between validity indices {#sec004}
------------------------------------------------

The 2 x 2-table representation ([Table 1](#pone.0231333.t001){ref-type="table"}) shows how the true prevalence, observed prevalence and the validity indices SE, SP, PPV and NPV are interrelated. Alternatively, these interrelations can be expressed in terms of the actual parameters themselves (and not the cell counts of the 2x2-table). Indeed, starting from the expression relating the observed prevalence to the true prevalence\[[@pone.0231333.ref007], [@pone.0231333.ref008]\] and from the definitions of PPV and NPV \[[@pone.0231333.ref009]\], we have the following system of algebraic equations with six unknown parameters; $$P = SE\mspace{360mu}\pi + \left( 1 - SP \right)\left( {1 - \pi} \right),$$ $$PPV = {{SE\mspace{360mu}\pi}/{\left( {SE\mspace{360mu}\pi + \left( 1 - SP \right)\left( {1 - \pi} \right)} \right),}}$$ $$NPV = {{SP\left( 1 - \pi \right)}/\left( {\left( {1 - SE} \right)\pi + SP\left( {1 - \pi} \right)} \right)}.$$

Hence, if we know three parameters, we can derive the others. The observed prevalence *P* is easily obtained by applying the CFA to the population in the database. Then, once we input two other parameters, the remaining parameters can be analytically derived by solving the system of algebraic equations above. For all combinations of *P* and any two other parameters, the analytical solutions for the remaining three parameters are given in [Table 2](#pone.0231333.t002){ref-type="table"}.

10.1371/journal.pone.0231333.t002

###### Overview of the interrelations between validity indices and the true prevalence, given the observed prevalenceP and two other parameters.

![](pone.0231333.t002){#pone.0231333.t002g}

  Known   Expressions                                                                                                                                                                                                                                        
  ------- ------------- -------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------
  1\.     Π, P, SE      $SP = 1 - \frac{\left( \text{P} - \text{SE} \times \Pi \right)}{\text{1-}\Pi}$   $PPV = \frac{SE \times \Pi}{P}$                                                                                                                     $NPV = 1 - \frac{\Pi\left( 1 - SE \right)}{1 - P}$
  2\.     Π, P, SP      $SE = \frac{P - \left( 1 - \Pi \right)\left( 1 - SP \right)}{\Pi}$               $PPV = 1 - \frac{\left( 1 - \Pi \right)\left( 1 - SP \right)}{P}$                                                                                   $NPV = \frac{SP\mspace{360mu}\left( 1 - \Pi \right)}{1 - P}$
  3\.     Π, P, PPV     $SE = \frac{P \times PPV}{\Pi}$                                                  $SP = 1 - \frac{P\left( 1 - PPV \right)}{1 - \Pi}$                                                                                                  $NPV = 1 - \frac{\Pi - P \times PPV}{1 - P}$
  4\.     Π, P, NPV     $SE = 1 - \frac{1 - \Pi - NPV\left( 1 - P \right)}{\Pi}$                         $SP = \frac{NPV\left( 1 - P \right)}{1 - \Pi}$                                                                                                      $PPV = 1 - \frac{1 - \Pi - NPV\left( 1 - P \right)}{P}$
  5\.     P, SE, SP     $\Pi = \frac{P + SP - 1}{SE + SP - 1}$                                           $PPV = 1 - \frac{\left( P - SE \right)\left( 1 - SP \right)}{P\mspace{360mu}\left( 1 - SP - SE \right)}$                                            $NPV = \frac{\left( {P - SE} \right)\mspace{360mu} SP}{\left( 1 - P \right)\left( 1 - SP - SE \right)}$
  6\.     P, SE, PPV    $\Pi = \frac{P \times PPV}{SE}$                                                  $SP = 1 - \frac{P\mspace{360mu}\left( {1 - PPV} \right)SE}{SE - P \times PPV}$                                                                      $NPV = 1 - \frac{\left( {1 - SE} \right)\mspace{360mu}\left( P \times PPV \right)}{SE\mspace{360mu}\left( 1 - P \right)}$
  7\.     P, SE, NPV    $\Pi = \frac{\left( 1 - P \right)\left( 1 - NPV \right)}{1 - SE}$                $SP = \frac{\left( {1 - P} \right)\left( {1 - SE} \right)\mspace{360mu} NPV}{\left( 1 - SE \right) - \left( 1 - P \right)\left( 1 - NPV \right)}$   $PPV = \frac{SE \times \left( 1 - P \right)\left( 1 - NPV \right)}{P\left( 1 - SE \right)}$
  8\.     P, SP, PPV    $\Pi = 1 - \frac{P \times \left( 1 - PPV \right)}{1 - SP}$                       $SE = \frac{P \times PPV\left( 1 - SP \right)}{1 - SP - P\left( 1 - PPV \right)}$                                                                   $NPV = \frac{P \times SP \times \left( 1 - PPV \right)}{\left( 1 - P \right)\left( 1 - SP \right)}$
  9\.     P, SP, NPV    $\Pi = 1 - \frac{\left( {1 - P} \right) \times NPV}{SP}$                         $SE = \frac{P \times SP - \left( {1 - SP} \right)\left( {1 - P} \right)\mspace{360mu} NPV}{SP - \left( {1 - P} \right) \times NPV}$                 $PPV = \frac{P \times SP - \left( {1 - SP} \right)\left( {1 - P} \right)NPV}{P \times SP}$
  10\.    P, PPV, NPV   $\Pi = \left( {1 - P} \right)\left( {1 - NPV} \right) + P \times PPV$            $SE = \frac{P \times PPV}{\left( {1 - P} \right)\left( {1 - NPV} \right) + P \times PPV}$                                                           $SP = \frac{\left( {1 - P} \right) \times NPV}{1 - \left( P \times PPV + \left( {1 - P} \right)\left( {1 - NPV} \right) \right)}$

The true prevalence, observed prevalence and the four validity indices are all (conditional) probabilities, and hence are bounded between zero and one. This imposes constraints on the input parameters without which the analytically derived parameters might be outside the zero-to-one range (constraints in [S1 Table](#pone.0231333.s001){ref-type="supplementary-material"}). More restrictive constraints result if we impose that the CFA should detect disease better than chance alone \[[@pone.0231333.ref007]\] (constraints in [S2 Table](#pone.0231333.s002){ref-type="supplementary-material"}). A CFA performs better than chance if it selects diseased persons with a higher probability than it does non-diseased persons. Note that the issue of a CFA performing worse than chance is easily alleviated through swapping the CFA-results, i.e. by re-labeling the CFA-positive results as negative and vice versa.

Finally, if the uncertainty associated with some of the input parameters is known, the uncertainty can be propagated to the derived parameters through Monte Carlo (MC) sampling. In this process, repeated samples from the statistical distributions of the input parameters are drawn. As the input parameters are all probabilities, it is naturally to assign beta distributions to them\[[@pone.0231333.ref010]\]. Then, for each MC sample of three input parameters, the remaining parameters are derived. This results in a distribution of derived parameters, based on which uncertainty intervals (UIs) can be derived \[[@pone.0231333.ref011]\]. As the true prevalence, observed prevalence and the validity indices are correlated, the MC sampling should ideally reflect this. Not accounting for correlation among the parameters might result in too wide UIs and in sampling parameter combinations that violate the constraints above. However, the correlations among the parameters are typically unknown. Therefore, we used independent sampling but rejected the invalid parameter combinations as defined by the constraints in [S1 Table](#pone.0231333.s001){ref-type="supplementary-material"} or [S2 Table](#pone.0231333.s002){ref-type="supplementary-material"}.

Web-application {#sec005}
---------------

To allow users to easily explore the interrelations between the true prevalence, observed prevalence and the validity indices SE, SP, PPV and NPV, we developed a web application using R \[[@pone.0231333.ref012]\] and the Shiny package \[[@pone.0231333.ref013]\]. The application is available from <https://apps.p-95.com/Interr/>. The application calculates the validity indices given user-defined values of the observed prevalence and any other two parameters. Optionally, the 95% percentile UIs of the derived parameters are calculated through MC simulation when the 95% confidence intervals (CIs) of the known parameters are provided. More specifically, we assign beta distributions to all known parameters for which CIs are provided, with the shape parameters of the beta distribution derived from the provided mean values and CIs based on the method of moments \[[@pone.0231333.ref014]\]. Invalid combinations of parameter values are discarded and the percentages of constraint violations are reported. We provide two types of UIs, one with the 'bounded between 0 and 1' constraints applied ([S1 Table](#pone.0231333.s001){ref-type="supplementary-material"}) and one with the more restrictive 'better than chance' constraints applied ([S2 Table](#pone.0231333.s002){ref-type="supplementary-material"})

To demonstrate the web-application, we used published results on the validation of two CFAs, one for intussusception and one for pneumonia, and derived any three indices using the other two as input parameters.

2.4. Sensitivity analyses {#sec006}
-------------------------

We additionally conducted sensitivity analyses to investigate the impact of estimation error in the input parameters on the derived parameters. For every combination of the observed prevalence and any two other parameters, we varied the input parameters one-at-the-time (OAT) while keeping the remaining input parameters at their baseline values \[[@pone.0231333.ref015]\]. Specifically, the input parameters *p* are varied between an under- and an overestimation with one standard error s.e. (i.e. between *p* − *s*. *e*. and *p* + *s*. *e*.) with s.e. calculated for the binomial proportion *p* from a sample of size 1000. We investigated three baseline scenarios for varying levels of *π* = {0.01, 0.05, 0.2} while keeping SE and SP fixed at 0.75 and 0.99, respectively. The corresponding baseline values for the observed prevalence and the predictive values were *P* = {0.02, 0.05, 0.16}, *PPV* = {0.43, 0.80, 0.95} and *NPV* = {1.0, 0.99, 0.94}. The biases of the derived indices are expressed relative to their standard errors as well. For the sensitivity analyses, we applied the less restrictive 'bounded between 0 and 1' constraints.

3. Results {#sec007}
==========

3.1. Illustrations {#sec008}
------------------

Ducharme et al conducted a validation study of the diagnostic, procedural, and billing codes for the identification of intussusception in children \<18 years living in the Census Metropolitan Area of Ottawa (Ontario, Canada) between 1995 and 2010 \[[@pone.0231333.ref016]\]. The authors calculated SE, SP, PPV, and NPV using manual validation of hospital records using the Brighton Collaboration diagnostic criteria as a gold standard. Case finding algorithms were based on a single or combination of ICD-9 diagnosis codes, procedure codes, and billing codes. Among the 417,997 patients, 185 patients (0.044%) met the case criteria according to the CFA chosen by the authors and 150 patients (0.036%) where intussusception cases. The CFA's PPV was 72.4% (95%CI: 65.4--78.7) and the SE was 89.3% (95% CI: 83.3--93.8), while both the NPV and the SP were \>99.9% (95% CI: \>99.9--100.0). Starting from the observed prevalence, SE and PPV, we derived the NPV and SP ([Fig 1](#pone.0231333.g001){ref-type="fig"}). The derived values for SP and NPV were the same as those reported in the paper. The true prevalence was derived to be 0.036% (95% UI: 0.034--0.038), equal to the study estimate. Starting from the observed prevalence, the PPV and the true prevalence led to a SE of 88.5% (84.4--92.6), close to the study estimate of 89.3%.

![Intussusception; deriving true prevalence, specificity and negative predictive value from the observed prevalence, sensitivity and positive predictive value.](pone.0231333.g001){#pone.0231333.g001}

A second example was the validation study of claims-based pneumonia CFA. In a cross-sectional study of patients visiting the emergency department (ED) of a hospital in Salt Lake City, Utah during a 5-month period, Aronsky et al assessed the validity of five different claims-based pneumonia CFA against a 'gold standard' of manual review of each patient encounter \[[@pone.0231333.ref017]\]. Among 10828 ED encounters, 272 (2.51%) were cases of pneumonia according to the 'gold standard'. Their selected algorithm was positive for 219 encounters (2.02%). For this algorithm, the authors reported SE of 65.1% (95% CI: 59.2--70.5), SP of 99.6% (95% CI: 99.5--99.7), PPV of 80.8% (95% CI: 75.1--85.5), and NPV of 99.1% (95% CI: 98.9--99.3). First, we used as input the PPV and NPV. The derived SE and SP were the same as those reported in the paper, as well as the true prevalence (2.51%; 95% UI:2.4--2.6) ([Fig 2](#pone.0231333.g002){ref-type="fig"}). Second, we used PPV and an interval for the true prevalence (2.00--3.00%) as input parameters. The derived ranges for SE, SP and NPV were \[54.4--81.6\], \[99.6--99.6\] and \[98.6--99.6\]; all including the originally reported values.

![Pneumonia; deriving true prevalence, sensitivity and specificity from the observed prevalence, positive and negative predictive value.](pone.0231333.g002){#pone.0231333.g002}

3.2. Sensitivity analyses {#sec009}
-------------------------

The impact of changing the input parameters (from -1 s.e. to + 1 s.e.) on the output parameters is depicted by the vertical bars in Figs [3](#pone.0231333.g003){ref-type="fig"} and [4](#pone.0231333.g004){ref-type="fig"}. The biases of the derived indices are expressed relative to their standard errors as well and are truncated at ±3 s.e. For example, for the input parameter combination *π* − *P* − *SE* and when *π* = 0.01 ([Fig 3](#pone.0231333.g003){ref-type="fig"}: upper left panel), varying *π* from -1 s.e. to + 1 s.e, has a small impact on SE and NPV (\< 1 s.e. change in both directions), but a more substantial impact on PPV (\~2 s.e. change in both directions). The combined results indicate that for the scenarios investigated the estimation error of the derived parameters is smallest when using the parameter combination *P*--SE--PPV.

![Results of the sensitivity analyses: Investigating the impact of changing the input parameters from -1 to +1 standard error (s.e.) on the derived parameters for varying levels of true prevalence, π = {0.01, 0.05, 0.2}, SE = 0.95 and SP = 0.75.\
The bias of the derived indices are truncated at ±3 s.e.](pone.0231333.g003){#pone.0231333.g003}

![Results of the sensitivity analyses: Investigating the impact of changing the input parameters from -1 to +1 standard error (s.e.) on the derived parameters for varying levels of true prevalence, π = {0.3, 0.5, 0.7}, SE = 0.95 and SP = 0.75.\
The bias of the derived indices are truncated at ± 3 s.e.](pone.0231333.g004){#pone.0231333.g004}

4. Discussion {#sec010}
=============

Starting from the interrelations between the true disease prevalence, the observed prevalence (as estimated from the misclassified data) and the four validity indices *SE*, *SP*, *PPV* and *NPV*, we derived the analytical expressions (formulas) to obtain for every combination of the observed prevalence and two other parameters the remaining three parameters. To facilitate the use of these analytical expressions, we developed a freely available user-friendly web-application.

The analytical expressions and web-application can be used for various purposes. First, they can be used to adjust a prevalence estimate for outcome misclassification. The expression to derive the true prevalence from the observed prevalence, SE and SP was already published in the late 70's, and known as the Rogan-Gladen estimator \[[@pone.0231333.ref007]\]. Our application allows users to obtain an estimate of the true prevalence given an estimate of the observed prevalence and any two other validity indices. These expressions were previously used to adjust *Bordetella Pertussis* incidence rates from five European healthcare databases for outcome misclassification \[[@pone.0231333.ref018]\].

To the best of our knowledge, none of these analytical expressions were prior available besides the Rogan-Gladen estimator. Second, the analytical expressions can be used to derive validity indices that are otherwise difficult to obtain. Particularly SP and NPV require very large validation studies, especially in the case of rare diseases. Benchimol et al \[[@pone.0231333.ref003]\] conducted a systematic review of validation studies of CFAs and found that only 36.9% of the studies reported four or more validity indices. They found that the most common validity indices used to report the diagnostic accuracy of CFAs are SE (67.2%) and PPV (63.8%) and to a lesser extent SP (49.8%) and NPV (32.1%). Another review study found that most studies that validate diagnoses in the Clinical Practice Research Database (CPRD) were restricted to assessing the proportion of CFA-positive cases that were confirmed by medical record review or responses to questionnaires \[[@pone.0231333.ref019], [@pone.0231333.ref020]\], thus only providing an estimate of PPV whereas at least two validity indices are required to adjust a prevalence estimate for outcome misclassification. In such cases where only one validity index is reported, the remaining validity indices can be derived when an estimate of the true prevalence is available. Such an estimate of the true prevalence might be obtained from external data sources such as disease registers or national surveillance systems. Obviously, in this case, it is important to ensure that the external estimate applies to the database population under study. Third, the comparison of validation studies is often hampered by the use of different validity indices. The ability to convert indices will facilitate this comparison. Fourth, the possibility to independently estimate different validity indices using different validation samples (e.g. a sample of diseased subjects to estimate SE and another sample of CFA-positives to estimate PPV) will make validation more feasible. It will undoubtedly reduce the sample size requirements compared to a comprehensive validation study by which the 'gold standard' measure is obtained for a random sample of the database population. Especially for rare diseases, such validations studies are unfeasible as very large sample sizes are required to capture at least some diseased subjects.

The methodology of analytically deriving validity indices has limitations. The presence of sampling error or selection bias might result in invalid parameter combinations (i.e. resulting in derived parameters outside the \[0,1\] range or corresponding to a CFA that performs worse than chance). To investigate the impact of estimation error in the input parameters on the derived parameters we conducted sensitivity analyses. The results show that, for the scenarios we investigated, the parameter combinations *P*--SE--PPV resulted in the smallest estimation errors in the derived parameters. The assumptions applying to our analytical derivations are the same as those underlying the conventional 2 x 2-table representation of validity indices ([Table 1](#pone.0231333.t001){ref-type="table"}). These assumptions are that the true disease status is truly dichotomous and the dichotomous 'gold standard' measure reflects the true disease status without error. However, disease is not always absent or present and there might be an underlying continuous condition (i.e. spectrum of severity) on which classification of disease status is based, varying from the clear absence to the clear presence of disease. In such cases, the SE and SP depend on the distribution of the underlying condition, and hence on the true disease prevalence \[[@pone.0231333.ref020], [@pone.0231333.ref021]\]. On top, if the gold standard measure is erroneous, the validity indices will be biased \[[@pone.0231333.ref021]\]. The methodology applies to prevalence estimates and incidence proportions, and not to the more commonly used incidence rate. Also, and irrespective of the validation methodology used, the validity of CFAs might depend on many factors such as population characteristics, access to healthcare and the completeness of the medical information contained in the database, thereby limiting the generalizability of the validity indices to populations others than those for which the validity of the CFA was initially assessed \[[@pone.0231333.ref002], [@pone.0231333.ref019]\]. Finally, disease misclassification might be differential, meaning that the misclassification depends on the exposure status, which leads to biased estimates of the exposure-disease association in both directions \[[@pone.0231333.ref022]\]. In this case, it is important to obtain validity indices by exposure status.

Despite these limitations, we echo many others \[[@pone.0231333.ref002], [@pone.0231333.ref003], [@pone.0231333.ref005]\] that validation of CFAs is essential to permit proper interpretation of the results obtained from healthcare database studies. The estimated validity indices might ultimately be used to adjust estimates of disease occurrence \[[@pone.0231333.ref007]\] or risk \[[@pone.0231333.ref006]\] for misclassification or to adjust power calculations \[[@pone.0231333.ref023]\]. By providing the analytical expressions regarding the inter-relations of the observed prevalence, true prevalence and the most commonly used validity indices, we hope to contribute to a more widespread use of validation studies and their results.

Supporting information {#sec011}
======================

###### Constraints on the input parameters ensuring that the derived parameters belong to the interval \[0,1\].

(DOCX)

###### 

Click here for additional data file.

###### Parameter constraints corresponding to a case-finding algorithm that performs better than chance.

(DOCX)

###### 

Click here for additional data file.
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b\. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc. 

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>) . If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

5\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <http://journals.plos.org/plosone/s/supporting-information>.

6\. One of the noted authors is a group or consortium: ADVANCE consortium. In addition to naming the author group, please list the individual authors and affiliations within this group in the acknowledgments section of your manuscript. Please also indicate clearly a lead author for this group along with a contact email address.
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**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This work tried to address the relationship been the performance parameters, e.g. sensitivity, specificity, PPV, NPV, hidden and EMR disease prevalence. I don't think this work adds any value to the field as it obviously confused the disease prevalence which can be either detected by the EMR or the population. EMR encapsulates data from limited groups of patients, e.g. inpatient, outpatient, and ER settings, therefore, could be under or over report the disease prevalence. I don't think mathematically you can derive the hidden or true disease prevalence or the case finding algorithm performance by a simple analysis. The only validation approach is to establish a second site prospective trial with robust inclusion/exclusion design. Any case finding algorithm which survives the prospective learning transfer would be regarded as validated. In that regard, I suggest this work to be rejected.

Reviewer \#2: Bollaerts et al. validated the algorithms in healthcare databases, and probably more importantly, developed a freely available use-friendly web-application to facilitate the use of their analytical expressions. The manuscript provides important information and method for the community considering the growing need for using real world data to study health outcomes and to study safety and efficacy of pharmaceutical products.

The manuscript is overall well written and comprehensive, I only have minor comments;

1\. Provide a very brief how-to-use explanations for the web-application as a supplement.

2\. In the Definitions in the method section, add short descriptions for "true prevalence" of how the determinations of the proportion of the diseased usually are performed or obtained. Estimation of the true prevalence is not always available.

3\. Some of the labels in the Figure 3 and Figure 4 are not legible, please make sure that they will be.

Reviewer \#3: The paper is of great interest, given the increasing use of electronic healthcare records for epidemiological purposes (not restricted to pharmacoepidemiology). The formulas to derive validity indices and the user-friendly web-application are very useful when it is possible to apply them. As specified by the authors their accuracy depends on the presence of a solid and unbiased sample used for validation studies, as well as the presence of a reliable prevalence estimate, from which to derive other parameters.

The paper has been framed in the field of pharmacoepidemiology, although the derivation of validity indices can be applied to other filed, firstly descriptive epidemiology.

The correction for potential nondifferential misclassified outcomes in epidemiological study using derived validity indices is only mentioned in the paper and it should be better discussed with illustration in the field of pharmocoepidemiology.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Editor:

1\) Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming.

\[Reply\]: We checked the PLOS ONE's style requirements and formatted accordingly.

2). Please include your tables as part of your main manuscript and remove the individual files. Please note that supplementary tables (should remain/ be uploaded) as separate \"supporting information\" files.

\[Reply\]: Tables are included as part of the main manuscript

3\) We note that the Figures in your submission contain copyrighted images. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For more information, see our copyright guidelines: <http://journals.plos.org/plosone/s/licenses-and-copyright>.

\[Reply\]: The authors of the submitted manuscript are the copyright holders and agree with publishing these figures under the CC BY4.0 license

4). Thank you for stating the following in the Competing Interests section: \"The authors have declared that no competing interests exist.\" We note that one or more of the authors are employed by a commercial company: P95 Epidemiology and Pharmacovigilance. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors\' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

\[Reply\]: This work was funded by the Innovative Medicines Initiative (IMI) Joint Undertaking through the ADVANCE project \[№ 115557\]. P95 was one of the beneficiaries among the many public partners of this IMI project, including both commercial and non-commercial organisations.P95 did not fund this study and the web-application is made freely available.

Amended funding statement: This research was funded by the Innovative Medicines Initiative (IMI) Joint Undertaking through the ADVANCE project \[№ 115557\]. The IMI is a joint initiative (public-private partnership) of the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA) to improve the competitive situation of the European Union in the field of pharmaceutical research. The IMI provided support in the form of salaries for KB, TDS, CD and RG but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. AR and NA did not receive any financial compensation for their contribution to this research.

Competing interest statement: The authors have declared that no competing interests exist.

5\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <http://journals.plos.org/plosone/s/supporting-information>.

\[Reply\]: Figure captions of the Supporting Information files have been included at the end of the manuscript.

6\. One of the noted authors is a group or consortium: ADVANCE consortium. In addition to naming the author group, please list the individual authors and affiliations within this group in the acknowledgments section of your manuscript. Please also indicate clearly a lead author for this group along with a contact email address.

\[Reply\]: It was not meant to have a group authorship but rather acknowledge that this work was carried out under the auspices of the ADVANCE project. Therefore we suggest to omit 'on behalf of the ADVANCE consortium' from the author list and change the title as follows 'Outcome misclassification in electronic healthcare database studies: deriving validity indices -- A contribution from the ADVANCE project'.

Reviewer 1:

This work tried to address the relationship been the performance parameters, e.g. sensitivity, specificity, PPV, NPV, hidden and EMR disease prevalence. I don't think this work adds any value to the field as it obviously confused the disease prevalence which can be either detected by the EMR or the population. EMR encapsulates data from limited groups of patients, e.g. inpatient, outpatient, and ER settings, therefore, could be under or over report the disease prevalence. I don't think mathematically you can derive the hidden or true disease prevalence or the case finding algorithm performance by a simple analysis. The only validation approach is to establish a second site prospective trial with robust inclusion/exclusion design. Any case finding algorithm which survives the prospective learning transfer would be regarded as validated. In that regard, I suggest this work to be rejected.

\[Reply\]: Our paper does not address the issue of a potential lack of representativeness of the electronic healthcare database population for the population of interest. Instead, our paper aims to contribute to the issue of disease misclassification in database research. The title and the abstract has been modified to make this explicit.

Reviewer 2:

Reviewer \#2: Bollaerts et al. validated the algorithms in healthcare databases, and probably more importantly, developed a freely available use-friendly web-application to facilitate the use of their analytical expressions. The manuscript provides important information and method for the community considering the growing need for using real world data to study health outcomes and to study safety and efficacy of pharmaceutical products.

The manuscript is overall well written and comprehensive, I only have minor comments;

1\. Provide a very brief how-to-use explanations for the web-application as a supplement.

\[Reply\]: We developed a short user-manual which can be accessed from the link to the application <https://apps.p-95.com/Interr/>.

2\. In the Definitions in the method section, add short descriptions for "true prevalence" of how the determinations of the proportion of the diseased usually are performed or obtained. Estimation of the true prevalence is not always available.

\[Reply\]: We added the following sentence in the methods section: "Obtaining the true prevalence is not always possible and requires an error-free test."

3\. Some of the labels in the Figure 3 and Figure 4 are not legible, please make sure that they will be.

\[Reply\]: The labels of the figures have been enlarged to the extent possible.

Reviewer 3:

The paper is of great interest, given the increasing use of electronic healthcare records for epidemiological purposes (not restricted to pharmacoepidemiology). The formulas to derive validity indices and the user-friendly web-application are very useful when it is possible to apply them. As specified by the authors their accuracy depends on the presence of a solid and unbiased sample used for validation studies, as well as the presence of a reliable prevalence estimate, from which to derive other parameters.

The paper has been framed in the field of pharmacoepidemiology, although the derivation of validity indices can be applied to other filed, firstly descriptive epidemiology.

\[Reply\]: The first paragraph of the introduction has been modified to give a broader context to the methodology.

The correction for potential nondifferential misclassified outcomes in epidemiological study using derived validity indices is only mentioned in the paper and it should be better discussed with illustration in the field of pharmocoepidemiology.

\[Reply\]: The correction non-differential outcomes is described in the second paragraph of the discussion. We also add, as part of the paragraph mentioning the limitations, that disease misclassification can also be differential, and in this case, requires validity indices by exposure status.

10.1371/journal.pone.0231333.r003
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Dear Dr. Bollaerts,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.
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I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.
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